Purple Biotech Ltd
PPBT
$2.53
-$0.12-4.53%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | 63.33% | -- | |
| Gross Profit | -- | -- | -63.33% | -- | |
| SG&A Expenses | -- | -- | -16.37% | -3.22% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -- | -- | -0.88% | 8.40% | |
| Operating Income | -- | -- | 0.88% | -8.40% | |
| Income Before Tax | -- | -- | 8.19% | -3.38% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -- | -- | 8.19% | -3.38% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | 5.43% | 4.26% | |
| Net Income | -- | -- | 8.25% | -1.61% | |
| EBIT | -- | -- | 0.88% | -8.40% | |
| EBITDA | -- | -- | 0.70% | -8.55% | |
| EPS Basic | -- | -- | 24.31% | -3,946.81% | |
| Normalized Basic EPS | -- | -- | 16.46% | -185.37% | |
| EPS Diluted | -- | -- | 24.15% | -3,946.81% | |
| Normalized Diluted EPS | -- | -- | 16.46% | -185.37% | |
| Average Basic Shares Outstanding | -- | -- | 22.44% | -16.93% | |
| Average Diluted Shares Outstanding | -- | -- | 22.44% | -16.93% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |